BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

NanoSmart Pharmaceuticals, Inc. Joins Forces with Children's Hospital Los Angeles to Fight Pediatric Cancer


11/1/2011 11:35:04 AM

ORANGE COUNTY, Calif., Nov. 1, 2011 /PRNewswire/ -- NanoSmart Pharmaceuticals, Inc., a corporation developing novel cancer pharmaceuticals, has entered into a research collaboration with Children's Hospital Los Angeles, one of the nation's top pediatric hospitals, to develop and assess NanoSmart's novel drug-delivery platform.

NanoSmart is developing a tumor-targeting platform utilizing human autoimmune antibodies that target areas of necrosis found in many different types of cancer. By combining these antibodies with different cancer drugs, NanoSmart plans to develop numerous novel biopharmaceutical products. NanoSmart's drug-delivery system promises to increase the safety and efficacy of existing cancer drugs by increasing localization at the tumor site.

Collaborative research with Children's Hospital Los Angeles will be conducted under the guidance of Timothy Triche, MD, PhD, Professor of Pathology and Pediatrics and Director of the Children's Hospital Los Angeles Department of Pathology's Center for Personalized Medicine.

"We are pleased to work with NanoSmart as part of our ongoing research program in nanoparticle-mediated therapy of Ewing's sarcoma. This research will complement other research currently in progress in our lab. It is unique in that NanoSmart has leveraged a naturally occurring human antibody to target the nanoparticles to the tumor, which if successful should facilitate rapid approval from the FDA for use on Ewing's sarcoma patients," said Dr. Triche.

"This strategic alliance will give NanoSmart access to critical preclinical and clinical resources," said Dr. James Smith, President of NanoSmart Pharmaceuticals. "In addition to Dr. Triche's expertise and guidance, we look forward to initial characterization and testing of NanoSmart's formulations in the unique model of metastatic Ewing's Sarcoma at Children's Hospital."

About Children's Hospital Los Angeles

Children's Hospital Los Angeles has been named the best children's hospital in California and among the best in the nation for clinical excellence with its selection to the prestigious US News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. The hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California. For more information, visit www.CHLA.org.

NanoSmart Pharmaceuticals, Inc.

For more information visit:
www.nanosmartpharma.com

CONTACT:
Tel: (949) 305-2020
info@nanosmartpharma.com

SOURCE NanoSmart Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES